Shares of Kura Oncology Inc. (NASDAQ:KURA) have received a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that cover the stock, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy rating.

Brokers have set a 1 year consensus price objective of $20.00 for the company and are predicting that the company will post ($0.41) EPS for the current quarter, according to Zacks. Zacks has also given Kura Oncology an industry rank of 92 out of 265 based on the ratings given to related companies.

A number of equities research analysts have recently commented on KURA shares. Zacks Investment Research cut shares of Kura Oncology from a “hold” rating to a “sell” rating in a report on Tuesday. Oppenheimer Holdings Inc. reiterated an “outperform” rating and set a $16.00 price target on shares of Kura Oncology in a report on Sunday, August 14th.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Kura Oncology (NASDAQ:KURA) traded down 1.14% on Tuesday, reaching $6.91. 44,901 shares of the company were exchanged. Kura Oncology has a 12-month low of $2.50 and a 12-month high of $25.00. The firm’s market capitalization is $129.51 million. The firm has a 50-day moving average of $5.36 and a 200 day moving average of $3.93.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Wednesday, August 10th. The company reported ($0.36) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.34) by $0.02. On average, equities analysts predict that Kura Oncology will post ($1.58) earnings per share for the current year.

A hedge fund recently bought a new stake in Kura Oncology stock. Minerva Advisors LLC acquired a new position in shares of Kura Oncology Inc. (NASDAQ:KURA) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 361,737 shares of the company’s stock, valued at approximately $977,000. Minerva Advisors LLC owned 1.96% of Kura Oncology as of its most recent filing with the SEC. Hedge funds and other institutional investors own 43.63% of the company’s stock.

About Kura Oncology

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

5 Day Chart for NASDAQ:KURA

Get a free copy of the Zacks research report on Kura Oncology (KURA)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with's FREE daily email newsletter.